Navigation Links
Cardiogenesis Reports Third Quarter 2008 Results
Date:11/13/2008

NSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share amounts)

(unaudited)

Three months ended Nine months ended

September 30, September 30,

2008 2007 2008 2007

Net revenues $2,618 $3,486 $9,719 $9,292

Cost of revenues 474 739 1,589 1,913

Gross profit 2,144 2,747 8,130 7,379

Operating expenses:

Research and development 165 103 633 612

Sales and marketing 1,536 1,246 4,858 3,268

General and administrative 753 719 2,404 2,611

Total operating expenses 2,454 2,068 7,895 6,491

Operating (loss) income (310) 679 235 888

Other income (expense):

Interest expense (1) (10) (22) (59)

Interest income 13 29 55 94

Non-cash interest expense -- (13) -- (89)

Change in fair value of

derivatives -- (133) -- (323)

Other non-cash income, net -- 38 -- 151

Total other income (expense), net 12 (89) 33 (226)

(Loss) income before

income taxes (298) 590 268 662

Tax provision 10 -- 10 --

Net (loss) income $(308) $590 $258 $662

Net (loss) earnings per share:

Basic $(0.01) $0.01 $0.01 $0.01

Dilute
'/>"/>

SOURCE Cardiogenesis Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cardiogenesis Reports Fourth Quarter and Full Year 2007 Results
2. Cardiogenesis Corporation to Report Third Quarter 2007 Results on November 14th
3. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
4. Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. China Biologic Products Reports Strong Third Quarter 2008 Results
6. Imagenetix, Inc. Reports Second Quarter and Six Month Results
7. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
8. China-Biotics, Inc. Reports Second Quarter 2009 Financial Results
9. Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
10. Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year
11. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
(Date:1/14/2014)... 2014 Kerr Corporation, a leading manufacturer of ... how-to information about dual arch impressions on its dental blog. ... Impressions,” the blog entry serves up a list of tips ... step-by-step demonstration by Dr. David Little as he crafts a ...
(Date:1/14/2014)... 2014 Independent publisher Bitingduck Press, with ... Canada, has big ideas for 2014 in production and ... are to produce high-quality, low-cost, DRM-free ebooks and to ... , The first major development will be bookstore ...
(Date:1/14/2014)... MO (PRWEB) January 14, 2014 Holloway ... comprehensive database of material test reports (MTRs) for all ... fabricates. Documenting test results is particularly important for equipment ... regulations. The MTR Library features search functionality that allows ...
Breaking Biology Technology:Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Bitingduck Press Looks Forward to 2014 With Multimedia E-books 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... and NEWTON, Mass., April 17 ,InforMedix Holdings, ... and Med-eXpert(TM) Systems to improve,medication adherence and ... prescription medication adherence solutions, announced an,agreement to ... to a broad spectrum of,Federal and State ...
... Professor,s fight against pancreatic cancer and underscores, his call-to-action for additional research ... ... of Lustgarten Foundation,s limited online book offer,as seen on ABC Primetime with Diane ... Last Lecture" were ...
... YORK, April 17 The market for congestive ... billion in 2007, and is,expected to reach $30 ... by,Kalorama Information, Congestive Heart Failure: Major World Markets, ... three factors: an,increased incidence of CHF, the application ...
Cached Biology Technology:InnovationRx, a Prescription Adherence Solutions Company, and InforMedix Partner to Market and Sell End-to-End Medication Adherence Solutions 2InnovationRx, a Prescription Adherence Solutions Company, and InforMedix Partner to Market and Sell End-to-End Medication Adherence Solutions 3InnovationRx, a Prescription Adherence Solutions Company, and InforMedix Partner to Market and Sell End-to-End Medication Adherence Solutions 4InnovationRx, a Prescription Adherence Solutions Company, and InforMedix Partner to Market and Sell End-to-End Medication Adherence Solutions 5The Lustgarten Foundation for Pancreatic Cancer Research Launches New Public Service Announcement Featuring 'Last Lecturer' Dr. Randy Pausch 2Genomics Likely to Replace Traditional Drug Therapies in Treating CHF 2
(Date:4/18/2014)... used techniques like X-ray crystallography and nuclear magnetic resonance ... structure of molecules, but such efforts have long been ... of a specific molecule and often in ordered and ... but impossible to peer into the structure of most ... soon be a thing of the past. , ...
(Date:4/18/2014)... as they,re planted may be good news for a garden. ... wild, a plant whose seeds sprouted at the first ,warm ... an insurance policy against late frosts or unexpected dry spells, ... Plants whose seeds put off sprouting until conditions are ... team of researchers working at the National Evolutionary Synthesis Center ...
(Date:4/17/2014)... clinical trials to treat tuberculosis could be the basis ... various bacteria, fungal infections and parasites, yet evade resistance, ... and collaborators. , Led by U. of I. chemistry ... the drug SQ109 attacks the tuberculosis bacterium, how the ... yeast to malaria and how targeting multiple pathways ...
Breaking Biology News(10 mins):MRI, on a molecular scale 2MRI, on a molecular scale 3Plants with dormant seeds give rise to more species 2Multitarget TB drug could treat other diseases, evade resistance 2
... the cells responsible for immune surveillance in the brain, ... tissue damage and infection. An international team under the ... shown that these cells may actually make a significant ... disease. About 1.2 million people are thought to suffer ...
... Washington, DC Scientists at the Lombardi Comprehensive Cancer ... five-year $7.5 million grant to tease apart in the ... protein receptor in breast cells in cancer development and treatment. ... kind of breast cancer and how she will fare during ...
... <A HREF=",http://chinese.eurekalert.org/zh/emb_releases/2010-03/asu-etb031810.php,">Chinese . TEMPE, Ariz. ... ban the export of electronics waste would likely make ... of an article from the journal Environmental Science ... call into question conventional thinking that trade bans can ...
Cached Biology News:Dangerous custodians 2Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 2Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 3E-waste trade ban won't end environmental threat 2
UV LAMP 254 NM 8 WATT, 1 EA. Category: Nucleid Acid Detection Systems....
UV LAMP 300 NM 8W T5, 1 EA. Category: Nucleid Acid Detection Systems....
... The SelectFX Alexa Fluor 488 Cytochrome c ... you need to detect cytochrome c in ... c primary antibody and an Alexa ... 488 dye exhibits bright green fluorescence that ...
Kit for Detection of Mitochondrial Membrane Potential...
Biology Products: